Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Exelixis, Inc. (EXEL : NSDQ)
 
 • Company Description   
Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Number of Employees: 954

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.26 Daily Weekly Monthly
20 Day Moving Average: 2,330,700 shares
Shares Outstanding: 320.74 (millions)
Market Capitalization: $6,498.21 (millions)
Beta: 0.74
52 Week High: $25.14
52 Week Low: $15.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.34% -2.85%
12 Week 3.58% 12.39%
Year To Date 10.83% 31.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1851 Harbor Bay Parkway
-
Alameda,CA 94502
USA		 ph: 650-837-7000
fax: 650-837-8300		 shubbard@exelixis.com http://www.exelixis.com
 
 • General Corporate Information   
Officers
Michael M. Morrissey - President and Chief Executive Officer
Stelios Papadopoulos - Chairman
Christopher J. Senner - Executive Vice President and Chief Financial Offic
Charles Cohen - Director
Carl B. Feldbaum - Director

Peer Information
Exelixis, Inc. (CORR.)
Exelixis, Inc. (RSPI)
Exelixis, Inc. (CGXP)
Exelixis, Inc. (BGEN)
Exelixis, Inc. (GTBP)
Exelixis, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30161Q104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 320.74
Most Recent Split Date: (:1)
Beta: 0.74
Market Capitalization: $6,498.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.88 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 37.33% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 22.98
Trailing 12 Months: 22.02
PEG Ratio: 0.62
Price Ratios
Price/Book: 2.83
Price/Cash Flow: 26.20
Price / Sales: 4.27
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -27.59%
Sales Growth
vs. Year Ago Period: 31.73%
vs. Previous Quarter: -21.09%
ROE
03/31/22 - 13.77
12/31/21 - 11.17
09/30/21 - 8.27
ROA
03/31/22 - 11.82
12/31/21 - 9.61
09/30/21 - 7.19
Current Ratio
03/31/22 - 6.37
12/31/21 - 5.43
09/30/21 - 6.17
Quick Ratio
03/31/22 - 6.28
12/31/21 - 5.35
09/30/21 - 6.06
Operating Margin
03/31/22 - 19.60
12/31/21 - 16.10
09/30/21 - 13.10
Net Margin
03/31/22 - 19.60
12/31/21 - 16.10
09/30/21 - 13.10
Pre-Tax Margin
03/31/22 - 25.08
12/31/21 - 20.50
09/30/21 - 16.29
Book Value
03/31/22 - 7.15
12/31/21 - 6.99
09/30/21 - 6.68
Inventory Turnover
03/31/22 - 1.94
12/31/21 - 2.01
09/30/21 - 1.98
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©